Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) insider Pravin Dugel sold 21,649 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $10.77, for a total value of $233,159.73. Following the transaction, the insider owned 2,525,429 shares of the company’s stock, valued at $27,198,870.33. This represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Ocular Therapeutix Stock Performance
Shares of NASDAQ:OCUL opened at $10.77 on Thursday. The business has a fifty day moving average of $9.63 and a 200-day moving average of $9.15. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.03 and a current ratio of 13.10. Ocular Therapeutix, Inc. has a twelve month low of $6.23 and a twelve month high of $16.44. The firm has a market cap of $2.37 billion, a PE ratio of -7.58 and a beta of 0.93.
Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05. Ocular Therapeutix had a negative net margin of 579.10% and a negative return on equity of 59.89%. The business had revenue of $13.47 million for the quarter, compared to the consensus estimate of $13.20 million. The firm’s quarterly revenue was down .1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.39) EPS. On average, equities research analysts predict that Ocular Therapeutix, Inc. will post -1.47 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on Ocular Therapeutix
Institutional Investors Weigh In On Ocular Therapeutix
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Principia Wealth Advisory LLC increased its position in shares of Ocular Therapeutix by 7.8% in the second quarter. Principia Wealth Advisory LLC now owns 440,618 shares of the biopharmaceutical company’s stock valued at $4,328,000 after acquiring an additional 31,918 shares during the last quarter. California State Teachers Retirement System grew its stake in Ocular Therapeutix by 854.8% in the second quarter. California State Teachers Retirement System now owns 2,040,439 shares of the biopharmaceutical company’s stock valued at $207,784,000 after purchasing an additional 1,826,733 shares in the last quarter. Kraematon Investment Advisors Inc. increased its position in shares of Ocular Therapeutix by 12.7% during the 2nd quarter. Kraematon Investment Advisors Inc. now owns 109,967 shares of the biopharmaceutical company’s stock worth $1,080,000 after purchasing an additional 12,350 shares during the last quarter. AlphaGrep UK Ltd bought a new stake in shares of Ocular Therapeutix during the 2nd quarter worth approximately $157,000. Finally, Raiffeisen Bank International AG boosted its holdings in shares of Ocular Therapeutix by 5.3% in the 2nd quarter. Raiffeisen Bank International AG now owns 100,000 shares of the biopharmaceutical company’s stock valued at $990,000 after buying an additional 5,000 shares during the last quarter. 59.21% of the stock is owned by institutional investors.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.
The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.
Featured Stories
- Five stocks we like better than Ocular Therapeutix
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.
